Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Daily capsule for patients with skin cancer

Patients with a rare form of skin cancer could now benefit from first-of-a-kind once daily capsule


Erivedge® (vismodegib), a new medicine that has been shown to help patients with a disfiguring and potentially life-threatening form of skin cancer, is now registered for use in New Zealand.

Erivedge is a first-in-class Hedgehog Pathway Inhibitor that helps shrink disfiguring or potentially life-threatening lesions in advanced skin cancer

AUCKLAND – 23 April 2014: From today, adult New Zealanders with metastatic basal cell carcinoma (mBCC) or locally advanced BCC (laBCC) where treatment with surgery or radiotherapy is inappropriate, could benefit from Erivedge®. 1 This makes Erivedge, a capsule taken once daily, the only registered medicine for advanced BCC (aBCC, is comprised of mBCC and laBCC) fulfilling an unmet medical need in this group of patients.1

BCC is the most common type of skin cancer in the world. 2 It is estimated that in 2006 there were 43,900 New Zealanders diagnosed with BCC and that this number is growing year on year.

BCC forms the majority (65% - 75%) of non-melanoma skin cancers (NMSC). In 2006, NMSC was estimated to have incurred NZ$51.4 million in healthcare costs (excluding GST) and NZ$6.7 million in lost production.

BCC is considered curable when confined to the skin.

However, in some cases the disease will invade surrounding tissue (locally advanced) or spread to other parts of the body (metastatic BCC) in a manner that cannot be effectively treated with surgery or radiation.
Dr Richard Martin, Cutaneous Surgical Oncologist, says that advanced basal cell carcinoma can be highly disfiguring and can significantly impact quality of life.

“Until now, there have not been any active treatment options available for patients who are not appropriate for surgery or radiotherapy. Erivedge, which has been shown to shrink tumours, addresses this unmet need and is a welcome new treatment option for patients with advanced BCC,” said Dr Martin.

An independent review facility assessment found that Erivedge shrank visible lesions in 43 percent (27/63) of patients with locally advanced BCC inappropriate for surgery or radiotherapy and shrank tumours in 30 percent (10/33) of those with metastatic BCC.

An application for funding will be submitted to PHARMAC in due course. In the interim, Erivedge will be available for private purchase .

-ENDS-

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Statistics: Net Annual Migration Passes 71,000

A record 71,300 more migrants arrived in New Zealand than left in the January 2017 year, Statistics New Zealand said today. This surpassed the previous annual record set in December 2016. More>>

ALSO:

Fossils: Ancient Penguins Lived Alongside Dinosaurs?

Penguins are much older than previously thought and their evolution probably dates back to the days of the dinosaurs, according to research on the fossilised leg bone and toes of a giant ancient penguin found in rocks near Waipara, North Canterbury. More>>

No Voda/Sky: Commission Declines Clearance For Merger

The Commerce Commission has declined to grant clearance for the proposed merger of Sky Network Television and Vodafone New Zealand. More>>

ALSO:

EARLIER:

Power: IEA Report On New Zealand's Energy System

Outside of its largely low-carbon power sector, managing the economy’s energy intensity and greenhouse gas emissions while still remaining competitive and growing remains a challenge. More>>

ALSO:

NASA: Seven Earth-Size Planets Around A Single Star

NASA's Spitzer Space Telescope has revealed the first known system of seven Earth-size planets around a single star. Three of these planets are firmly located in the habitable zone, the area around the parent star where a rocky planet is most likely to have liquid water. More>>

ALSO:

Auckland Transport Case: Men Guilty Of Corruption And Bribery Will Spend Time In Jail

Two men who were found guilty of corruption and bribery in a Serious Fraud Office (SFO) trial have been sentenced in the Auckland High Court today... The pair are guilty of corruption and bribery offences relating to more than $1 million of bribes which took place between 2005 and 2013 at Rodney District Council and Auckland Transport. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news